195 related articles for article (PubMed ID: 36714913)
1. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.
Petri M; Joyce D; Haag K; Fava A; Goldman DW; Zhong D; Xiao S; Milstone A; Magder LS
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1878-1885. PubMed ID: 36714913
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
[TBL] [Abstract][Full Text] [Related]
3. Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.
Parsons C; Rubio J; Boulougoura A; Krishfield S; Kyttaris V
Rheumatol Int; 2023 Sep; 43(9):1621-1627. PubMed ID: 37310438
[TBL] [Abstract][Full Text] [Related]
4. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
[TBL] [Abstract][Full Text] [Related]
6. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
[TBL] [Abstract][Full Text] [Related]
7. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
8. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
[TBL] [Abstract][Full Text] [Related]
9. Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.
Kikuchi J; Kondo Y; Kojima S; Kasai S; Sakai Y; Takeshita M; Hiramoto K; Saito S; Fukui H; Hanaoka H; Suzuki K; Kaneko Y
Immunol Med; 2024 Jun; 47(2):76-84. PubMed ID: 38189429
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE.
Reynolds JA; Faustini SE; Tosounidou S; Plant T; Ubhi M; Gilman R; Richter AG; Gordon C
Lupus; 2023 Mar; 32(3):431-437. PubMed ID: 36631440
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.
Sjöwall J; Azharuddin M; Frodlund M; Zhang Y; Sandner L; Dahle C; Hinkula J; Sjöwall C
Front Immunol; 2021; 12():724047. PubMed ID: 34512651
[TBL] [Abstract][Full Text] [Related]
12. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
13. Systemic Lupus Erythematosus and COVID-19.
Pappa M; Panagiotopoulos A; Thomas K; Fanouriakis A
Curr Rheumatol Rep; 2023 Oct; 25(10):192-203. PubMed ID: 37477841
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.
Mehta P; Gasparyan AY; Zimba O; Kitas GD
Clin Rheumatol; 2022 Sep; 41(9):2893-2910. PubMed ID: 35639259
[TBL] [Abstract][Full Text] [Related]
15. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
Mok CC; Chan KL; Tse SM
Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE.
Larsen ES; Nilsson AC; Möller S; Voss AB; Johansen IS
Clin Exp Rheumatol; 2023 Mar; 41(3):676-684. PubMed ID: 35894059
[TBL] [Abstract][Full Text] [Related]
18. The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab.
Tunitsky-Lifshitz Y; Maoz-Segal R; Niznik S; Shavit R; Haj Yahia S; Langevitz P; Agmon-Levin N
Lupus; 2023 Apr; 32(5):675-679. PubMed ID: 36952594
[TBL] [Abstract][Full Text] [Related]
19. The Use of COVID-19 Vaccines in Patients with SLE.
Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
